Abstract
A recent pilot study examined sequential treatment with methylphenidate with the later addition of Fluvoxamine, an SSRI antidepressant. Children with ADHD and anxiety were first titrated to an effective dose of methylphenidate. Those who responded favorably were then treated with Fluvoxamine. A total of 81% of participants responded to the methylphenidate, suggesting that children with this combined comorbidity do in fact respond to ADHD treatments. The benefits of adding Fluvoxamine were less clear than in prior studies as the response rate to the Fluvoxamine placebo was higher than expected. Fluvoxamine treatment in this study did not cause exacerbation of anxiety or physical symptoms. These results suggest that stimulants are as effective and safe in children with ADHD and comorbid anxiety as in those with ADHD alone.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
